Literature DB >> 18644436

Prions and the proteasome.

Pelagia Deriziotis1, Sarah J Tabrizi.   

Abstract

Prion diseases are fatal neurodegenerative disorders that include Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy in animals. They are unique in terms of their biology because they are caused by the conformational re-arrangement of a normal host-encoded prion protein, PrPC, to an abnormal infectious isoform, PrPSc. Currently the precise mechanism behind prion-mediated neurodegeneration remains unclear. It is hypothesised than an unknown toxic gain of function of PrPSc, or an intermediate oligomeric form, underlies neuronal death. Increasing evidence suggests a role for the ubiquitin proteasome system (UPS) in prion disease. Both wild-type PrPC and disease-associated PrP isoforms accumulate in cells after proteasome inhibition leading to increased cell death, and abnormal beta-sheet-rich PrP isoforms have been shown to inhibit the catalytic activity of the proteasome. Here we review potential interactions between prions and the proteasome outlining how the UPS may be implicated in prion-mediated neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644436     DOI: 10.1016/j.bbadis.2008.06.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Proteomic consequences of expression and pathological conversion of the prion protein in inducible neuroblastoma N2a cells.

Authors:  Monique Provansal; Stéphane Roche; Manuela Pastore; Danielle Casanova; Maxime Belondrade; Sandrine Alais; Pascal Leblanc; Otto Windl; Sylvain Lehmann
Journal:  Prion       Date:  2010-10-27       Impact factor: 3.931

Review 2.  Transmission of prions within the gut and towards the central nervous system.

Authors:  Gianfranco Natale; Michela Ferrucci; Gloria Lazzeri; Antonio Paparelli; Francesco Fornai
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

3.  Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.

Authors:  Pelagia Deriziotis; Ralph André; David M Smith; Rob Goold; Kerri J Kinghorn; Mark Kristiansen; James A Nathan; Rina Rosenzweig; Dasha Krutauz; Michael H Glickman; John Collinge; Alfred L Goldberg; Sarah J Tabrizi
Journal:  EMBO J       Date:  2011-07-08       Impact factor: 11.598

Review 4.  Lysosomal Quality Control in Prion Diseases.

Authors:  Priyanka Majumder; Oishee Chakrabarti
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 5.  Physiological and environmental control of yeast prions.

Authors:  Tatiana A Chernova; Keith D Wilkinson; Yury O Chernoff
Journal:  FEMS Microbiol Rev       Date:  2013-12-04       Impact factor: 16.408

6.  Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease.

Authors:  Mark S Hipp; Chetan N Patel; Kirill Bersuker; Brigit E Riley; Stephen E Kaiser; Thomas A Shaler; Michael Brandeis; Ron R Kopito
Journal:  J Cell Biol       Date:  2012-02-27       Impact factor: 10.539

7.  Gene expression profiling of mesenteric lymph nodes from sheep with natural scrapie.

Authors:  Hicham Filali; Inmaculada Martín-Burriel; Frank Harders; Luis Varona; Carlos Hedman; Diego R Mediano; Marta Monzón; Alex Bossers; Juan J Badiola; Rosa Bolea
Journal:  BMC Genomics       Date:  2014-01-23       Impact factor: 3.969

8.  Physical and Genetic Interactions Between Uls1 and the Slx5-Slx8 SUMO-Targeted Ubiquitin Ligase.

Authors:  Wei Tan; Zheng Wang; Gregory Prelich
Journal:  G3 (Bethesda)       Date:  2013-04-09       Impact factor: 3.154

9.  Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy.

Authors:  Jingjing Liang; Debra Parchaliuk; Sarah Medina; Garrett Sorensen; Laura Landry; Shenghai Huang; Meiling Wang; Qingzhong Kong; Stephanie A Booth
Journal:  BMC Genomics       Date:  2009-04-28       Impact factor: 3.969

10.  PiZ mouse liver accumulates polyubiquitin conjugates that associate with catalytically active 26S proteasomes.

Authors:  Christopher J Haddock; Keith Blomenkamp; Madhav Gautam; Jared James; Joanna Mielcarska; Edward Gogol; Jeffrey Teckman; Dorota Skowyra
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.